RESEARCH QUESTION Research into megakaryocyte activity has picked up in recent years, largely due to the introduction of more refined methods of studying these large multinucleated cells. More studies are being conducted on various molecules that may interact with and control megakaryocyte development, and subsequently their end-product, the platelets. The enzyme acetylcholinesterase (AchE) has...

Despite the importance of blood platelets in health and disease, the mechanisms regulating their formation within megakaryocytes are unknown. We generated mice lacking the hematopoietic subunit (p45) of the heterodimeric erythroid transcription factor NF-E2. Unexpectedly, NF-E2-/- mice lack circulating platelets and die of hemorrhage; their megakaryocytes show no cytoplasmic platelet formation....

Hereditary thrombocythemia is a rare autosomal dominant disorder caused by mutations in either the thrombopoietin gene (TPO) or its receptor c-MPL. TPO mutations described so far lead to thrombopoietin overproduction through increased translation of m-RNA. Unilateral transverse reduction limb defects are usually sporadic and generally thought to be caused by vascular disruptions. Reports of inh...

We develop a mathematical model of platelet, megakaryocyte, and thrombopoietin dynamics in humans. We show that there is a single stationary solution that can undergo a Hopf bifurcation, and use this information to investigate both normal and pathological platelet production, specifically cyclic thrombocytopenia. Carefully estimating model parameters from laboratory and clinical data, we then a...

Introduction: Thrombopoietin receptor agonists are commonly second-line drugs in immune thrombocytopenia (ITP) pharmacotherapy children and prescribed for chronic ITP refractory to first-line therapy.
 Standard children: includes prescribing glucocorticoids or intravenous immunoglobulins.
 agonists: Currently Romiplostim Eltrombopag used the Russian Federation pediatrics. Their pharma...